We are live on
!
Find out more
BI
BVF Inc Portfolio holdings
AUM
$3.91B
1-Year Est. Return
304.52%
This Fund
S&P 500
This Quarter
Est. Return
+38.64%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$2.54B
AUM Growth
+$706M
(+38%)
Cap. Flow
+$104M
Cap. Flow
% of AUM
4.08%
Top 10 Holdings %
Top 10 Hldgs %
54.04%
Holding
74
New
12
Increased
16
Reduced
23
Closed
6
Avg Time Held
6.9
quarters
Top 10 Avg Time Held
2.2
quarters
Top 20 Avg Time Held
2.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Olema Pharmaceuticals
OLMA
|
+$312M |
| 2 |
Amarin Corp
AMRN
|
+$46.6M |
| 3 |
4D Molecular Therapeutics
FDMT
|
+$45.7M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$40.9M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$31.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpringWorks Therapeutics
SWTX
|
+$132M |
| 2 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$87.3M |
| 3 |
Celldex Therapeutics
CLDX
|
+$45.5M |
| 4 |
Replimune Group
REPL
|
+$38.9M |
| 5 |
Xencor
XNCR
|
+$33.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.26% |
| 2 | Miscellaneous | 0.42% |
| 3 | Financials | 0.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Crescent Biopharma
CBIO
$489M
| $35.9M | 1.41% |
95,443
+23,000
| +32% | +$8.06M |
2019 Q3
5 quarters
|
|
27
DELISTED
Forte Biosciences
FBRX
| $26.2M | 1.03% |
28,752
-2,350
| -8% | -$2.21M |
2020 Q2
2 quarters
|
|
|
CALT
28
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
| $25.5M | 1% |
750,000
| – | – |
2020 Q2
2 quarters
|
|
29
Verastem
VSTM
$808M
| $23.8M | 0.94% |
931,750
+36,084
| +4% | +$725K |
2017 Q4
12 quarters
|
|
30
Immunovant
IMVT
$5.8B
| $23.8M | 0.93% |
514,370
-684,057
| -57% | -$31.6M |
2019 Q4
4 quarters
|
|
|
CTIC
31
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $22.3M | 0.88% |
6,929,690
| – | – |
2015 Q3
21 quarters
|
|
|
CALA
32
DELISTED
Calithera Biosciences, Inc
CALA
| $21.4M | 0.84% |
218,062
-11,220
| -5% | -$983K |
2018 Q3
9 quarters
|
|
33
DELISTED
Molecular Templates, Inc.
MTEM
| $20.2M | 0.79% |
143,270
| – | – |
2017 Q3
13 quarters
|
|
34
Syndax Pharmaceuticals
SNDX
$1.24B
| $19.5M | 0.77% |
878,524
-1,592,154
| -64% | -$33M |
2017 Q4
12 quarters
|
|
35
argenx
ARGX
$51.8B
| $18.4M | 0.72% |
62,491
-107,109
| -63% | -$29.4M |
2019 Q4
4 quarters
|
|
|
FPRX
36
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $17.7M | 0.7% |
1,038,678
-6,970,675
| -87% | -$87.3M |
2018 Q2
10 quarters
|
|
37
Cogent Biosciences
COGT
$4.93B
| $17.2M | 0.68% |
+1,532,282
| New | +$16.8M |
2020 Q4
0 quarters
|
|
38
Palvella Therapeutics
PVLA
$1.79B
| $13.7M | 0.54% |
68,682
| – | – |
2016 Q2
18 quarters
|
|
|
PNT
39
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $13.3M | 0.52% |
954,996
-45,004
| -5% | -$625K |
2020 Q3
1 quarter
|
|
40
Eledon Pharmaceuticals
ELDN
$189M
| $11.8M | 0.46% |
763,279
+567,953
| +291% | +$10.8M |
2019 Q2
6 quarters
|
|
|
GMDA
41
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $11.3M | 0.44% |
1,343,667
-800,000
| -37% | -$5.41M |
2019 Q2
6 quarters
|
|
42
Lite Strategy Inc
LITS
$35.3M
| $10.7M | 0.42% |
202,458
-1,550
| -0.8% | -$89.4K |
2018 Q2
10 quarters
|
|
43
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $10.6M | 0.42% |
+2,695,418
| New | +$8.15M |
2020 Q4
0 quarters
|
|
44
Ovid Therapeutics
OVID
$416M
| $10.4M | 0.41% |
4,522,051
+900,000
| +25% | +$4.19M |
2019 Q1
7 quarters
|
|
45
Cartesian Therapeutics
RNAC
$197M
| $10M | 0.39% |
110,165
-171,820
| -61% | -$14.9M |
2019 Q4
4 quarters
|
|
|
GNCA
46
DELISTED
Genocea Biosciences, Inc.
GNCA
| $9.71M | 0.38% |
4,012,404
| – | – |
2018 Q1
11 quarters
|
|
47
Tango Therapeutics
TNGX
$3.71B
| $9.15M | 0.36% |
800,000
| – | – |
2020 Q3
1 quarter
|
|
|
CFRX
48
DELISTED
ContraFect Corporation
CFRX
| $8.08M | 0.32% |
20,000
| – | – |
2020 Q2
2 quarters
|
|
49
DELISTED
Cidara Therapeutics
CDTX
| $7.48M | 0.29% |
186,985
-1,350
| -0.7% | -$67.1K |
2018 Q2
10 quarters
|
|
50
Corvus Pharmaceuticals
CRVS
$788M
| $6.92M | 0.27% |
1,943,712
+200,000
| +11% | +$805K |
2017 Q2
14 quarters
|
|
Similar funds
LFCM
DCM
LNC
GL
AC
FFGIM
AIM
LCM
BVF Inc's Q4 2020 Portfolio in Review
As of Q4 2020, BVF Inc held 74 positions worth $2.54B, up 38% from $1.84B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
BVF Inc deployed $104M of net new capital in Q4 2020, opening 12 new positions and adding to 16 existing holdings. Its largest new stake was Olema Pharmaceuticals: 6,661,503 shares worth $320M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $132M trimmed.
- BVF Inc's largest Q4 2020 buy was Olema Pharmaceuticals: 6,661,503 shares worth $320M.
- BVF Inc added most to Amarin Corp in Q4 2020, an estimated $46.6M increase.
- BVF Inc's biggest Q4 2020 reduction was SpringWorks Therapeutics, cutting an estimated $132M.
- BVF Inc fully exited Celldex Therapeutics in Q4 2020, selling an estimated $45.5M.
- BVF Inc's ten largest holdings make up 54% of its $2.54B portfolio in Q4 2020.
- BVF Inc opened 12 new positions and closed 6 in Q4 2020.
- BVF Inc's portfolio value rose 38% quarter-over-quarter to $2.54B.
Based on BVF Inc's 13F filing for Q4 2020, filed 12 Feb 2021.